Phase II Study of Doxifluridine in Advanced Squamous Cell Carcinoma of the Head and Neck

Overview

Journal Eur J Cancer Clin Oncol

Specialty Oncology

Date 1984 Mar 1

PMID 6231185

Citations 6

Authors

R Abele

E Kaplan

R Grossenbacher

H J SCHMID

F Cavalli

Affiliations

Soon will be listed here.

Abstract

We conducted a phase II trial with 5'-deoxy-5-fluoridine (doxifluridine) in advanced squamous cell carcinoma of the head and neck. The drug was given at the dose of 4 g/m2 daily X 5 every 3 weeks. Twenty eligible patients entered this trial, 12 being evaluable for response to doxifluridine. The majority of these patients received previous treatment for cancer. One complete and two partial remissions were observed (25%). Drug-induced toxicity consisted mainly of myelosuppression, mild nausea and vomiting, stomatitis and central nervous system side-effects. Other dosages or schedules for doxifluridine administration might be explored in poor-risk patients.

Citing Articles

The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Yates M, Seley-Radtke K Antiviral Res. 2018; 162:5-21.

PMID: 30529089 PMC: 6349489. DOI: 10.1016/j.antiviral.2018.11.016.

Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.

Fossa S, Dahl O, HOEL R, Heier M, Loeb M Cancer Chemother Pharmacol. 1985; 15(2):161-3.

PMID: 2990750 DOI: 10.1007/BF00257528.

Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry.

Malet-Martino M, Servin P, Bernadou J, Armand J, Martino R Invest New Drugs. 1987; 5(3):273-9.

PMID: 2959633 DOI: 10.1007/BF00175298.

Phase I/II tolerability/pharmacokinetic study with one-hour intravenous infusion of doxifluiridine (5'-dFUrd) 3 g/m2 VS 5 g/m2 QD x 5 per month.

Fossa S, Flokkmann A, Heier M, Aas M, Moe B, HEINTZ R Cancer Chemother Pharmacol. 1986; 18(3):252-6.

PMID: 2948731 DOI: 10.1007/BF00273397.

Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma.

Alberto P, Rozencweig M, Clavel M, Siegenthaler P, Cavalli F, Gundersen S Cancer Chemother Pharmacol. 1986; 16(1):78-9.

PMID: 2933177 DOI: 10.1007/BF00255292.